Mirum Pharmaceuticals (MIRM) Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum's LIVMARLI streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
- Results demonstrate 70% risk reduction for long-term clinical outcomes in patients with Alagille syndrome treated with LIVMARLI
- Data are the first to demonstrate a six-year transplant-free.
Mirum Pharmaceuticals, Inc. today announced that Hepatology published an analysis demonstrating a statistically significant improvement in six-year event-free and transplant-free survival in patients with Alagille syndrome (ALGS) treated with.
Mirum Pharmaceuticals (MIRM) Presents Long-Term LIVMARLI Data and New Alagille Syndrome Caregiver Burden Analysis streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
CANbridge Pharmaceuticals CAN108 New Drug Application/Orphan Drug Registration (NDA/ORD) for Alagille Syndrome Accepted by the Taiwan Food and Drug Administration - read this article along with other careers information, tips and advice on BioSpace